Top Page
Mayne Pharma Group
(Sydney:MYX)
Mayne Pharma Group (MYX) vs. iShares MSCI Australia ETF (EWA)
Mayne Pharma Group Business Overview & Revenue Model
Mayne Pharma Group Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 413.53M | 388.15M | 183.59M | 157.15M | 400.78M | 456.99M | Gross Profit |
| 243.85M | 218.53M | 26.84M | 23.75M | 127.02M | 140.94M | EBIT |
| -13.60M | -45.86M | -186.44M | -121.88M | 1.36M | -12.13M | EBITDA |
| 47.87M | -116.93M | -193.80M | -78.88M | -182.40M | -34.03M | Net Income Common Stockholders |
| -129.23M | -174.23M | -316.42M | -281.29M | -208.42M | -92.79M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 30.70M | 149.28M | 229.24M | 97.08M | 98.35M | 138.19M | Total Assets |
| 189.66M | 1.14B | 1.25B | 1.30B | 1.48B | 1.84B | Total Debt |
| 0.00 | 38.82M | 47.51M | 413.67M | 346.82M | 398.05M | Net Debt |
| -30.38M | -71.25M | -54.21M | 316.59M | 248.47M | 259.85M | Total Liabilities |
| 82.50M | 688.99M | 613.77M | 764.89M | 706.56M | 799.91M | Stockholders Equity |
| 107.16M | 454.19M | 634.36M | 545.88M | 768.36M | 1.04B |
| Cash Flow | Free Cash Flow | ||||
| -11.26M | -36.16M | -262.71M | -28.47M | 22.16M | 52.66M | Operating Cash Flow |
| 391.00K | -15.30M | -43.12M | -16.62M | 47.26M | 99.78M | Investing Cash Flow |
| -58.75M | 53.45M | 473.49M | -28.53M | -49.25M | -55.87M | Financing Cash Flow |
| 91.00K | -19.85M | -431.48M | 37.01M | -28.83M | 4.52M |
Mayne Pharma Group Technical Analysis
Mayne Pharma Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% | |
38 Underperform | $407.85M | ― | -23.92% | ― | 52.96% | 45.68% | |
| $141.46M | 19.74 | 17.87% | ― | ― | ― | ||
| $256.18M | ― | -31.16% | ― | ― | ― | ||
53 Neutral | AU$723.04M | ― | -53.99% | ― | ― | -40.19% | |
50 Neutral | AU$328.42M | ― | -524.68% | ― | 322.26% | -53.98% | |
44 Neutral | AU$116.69M | ― | -35.20% | ― | 4.68% | -155.42% |
Mayne Pharma Group Corporate Events
Mayne Pharma Group has announced that Mitsubishi UFJ Financial Group, through its subsidiary First Sentier Investors Holdings Pty Limited, has acquired a substantial holding in the company. This acquisition grants Mitsubishi UFJ Financial Group significant voting power and influence over Mayne Pharma’s operations, potentially impacting its strategic direction and market positioning.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.69 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has announced that the Supreme Court of New South Wales has approved the distribution of a Supplementary Scheme Booklet to its shareholders, following a notice from Cosette Pharmaceuticals intending to terminate a previous scheme implementation deed. Despite this development, the scheduled Scheme Meeting on 18 June 2025 will proceed as planned, with the company’s directors unanimously recommending shareholders vote in favor of the proposed scheme of arrangement, barring any superior proposals.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has received a notice from Cosette Pharmaceuticals purporting to terminate their Scheme Implementation Deed (SID) due to an alleged material adverse change. Mayne Pharma disputes this claim, asserting that no such change has occurred and intends to reject the termination notice as invalid. The company is considering legal action to enforce its rights under the SID and remains committed to completing the scheme for the benefit of its shareholders.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has provided an update regarding its Scheme of Arrangement with Cosette Pharmaceuticals. Despite Cosette’s assertion of a material adverse change, Mayne Pharma has not received a termination notice, and the company remains committed to completing the scheme. Additionally, the FDA has issued a close-out letter confirming that Mayne Pharma has addressed previously identified issues. The company is determined to enforce its rights under the scheme implementation deed and encourages shareholders to participate in the upcoming Scheme Meeting.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Goldman Sachs Group, Inc. has increased its voting power in Mayne Pharma Group Limited from 7.54% to 8.55% by acquiring additional fully paid ordinary shares. This change in substantial holding indicates a growing interest and investment by Goldman Sachs in Mayne Pharma, potentially impacting the company’s market positioning and signaling confidence in its future prospects.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
UBS Group AG and its related bodies corporate have increased their voting power in Mayne Pharma Group Limited, a company in the pharmaceutical industry, from 5.77% to 6.83% as of May 29, 2025. This change in substantial holding reflects UBS’s strategic interest in Mayne Pharma, potentially impacting the company’s market dynamics and signaling a shift in shareholder influence and control.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has filed a complaint against TherapeuticsMD, Inc. in the United States District Court for the District of Delaware, alleging breach of contract and fraud. The complaint seeks over US$11.5 million in damages due to alleged misrepresentations by TherapeuticsMD about commercialisation assets sold to Mayne Pharma. Additionally, Mayne Pharma has filed a motion to dismiss TherapeuticsMD’s legal proceeding, which it believes to be without merit.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
UBS Group AG and its related bodies corporate have reduced their voting power in Mayne Pharma Group Limited from 7.26% to 5.77% as of May 23, 2025. This change in substantial holding reflects a shift in UBS’s investment strategy, potentially impacting Mayne Pharma’s shareholder dynamics and market perception.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Goldman Sachs Group, Inc. has increased its voting power in Mayne Pharma Group Limited from 6.14% to 7.54%, as indicated in a recent notice of change of interests of a substantial holder. This change reflects a significant shift in the ownership structure of Mayne Pharma, potentially impacting the company’s governance and strategic direction, and signaling increased confidence from a major financial institution.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has entered into a Scheme Implementation Deed with Cosette Pharmaceuticals Inc, under which Cosette will acquire 100% of Mayne Pharma’s shares through a scheme of arrangement. The company has been sharing information with Cosette as part of this agreement, including a non-material Untitled Letter related to a speaker presentation for NEXTSTELLIS®. Mayne Pharma confirmed that the letter does not impact its ability to sell and distribute NEXTSTELLIS® in the United States and does not consider it materially price sensitive, thus not requiring market disclosure.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited is currently involved in a scheme implementation deed with Cosette Pharmaceuticals, where Cosette proposes to acquire all shares of Mayne Pharma. Recently, Cosette claimed a material adverse change in Mayne Pharma’s trading performance, which Mayne Pharma disputes. Despite Cosette’s assertions, Mayne Pharma maintains that no such change has occurred and is committed to progressing the scheme as planned. The company has rejected Cosette’s claims and reminded them of their obligations under the agreement, while remaining open to discussions to resolve the issue.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
UBS Group AG and its related bodies have reduced their voting power in Mayne Pharma Group Limited from 8.79% to 7.26%, reflecting a change in their substantial holding. This adjustment in UBS’s stake could influence the company’s shareholder dynamics and potentially impact its strategic decisions, as substantial holders often play a significant role in corporate governance.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has requested a trading halt on its securities pending a significant announcement regarding a proposed acquisition by Cosette through a scheme of arrangement. This move indicates a strategic shift that could impact the company’s market positioning and stakeholder interests, as the trading halt will remain until the announcement is made or normal trading resumes.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has announced the registration of its Scheme Booklet with the Australian Securities and Investments Commission, detailing the proposed acquisition by Cosette Pharmaceuticals via a scheme of arrangement. The Independent Expert has deemed the acquisition fair and reasonable, recommending shareholders vote in favor of the scheme. The Scheme Meeting is scheduled for June 18, 2025, where shareholders will decide on the proposal, which is expected to impact Mayne Pharma’s market positioning and shareholder value.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.69 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has announced that the Supreme Court of New South Wales has approved the convening of a shareholder meeting to consider a proposed acquisition by Cosette Pharmaceuticals, Inc. The meeting will allow shareholders to vote on the scheme of arrangement, which has been deemed fair and reasonable by an independent expert. The expert’s report values Mayne Pharma shares within a range that aligns with the proposed acquisition price, and the company’s directors unanimously recommend shareholders vote in favor of the scheme. The outcome of this acquisition could significantly impact Mayne Pharma’s operations and market positioning, providing potential benefits to stakeholders.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma has addressed market speculation following an FDA ‘untitled letter’ concerning promotional claims for its contraceptive product, NEXTSTELLIS®. The company has voluntarily withdrawn the presentation in question but states that the letter does not affect its ability to sell NEXTSTELLIS® in the U.S. or impact its stock price. Mayne Pharma plans to proceed with its Scheme of Arrangement with Cosette as scheduled.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited recently experienced a notable drop in its share price, which prompted a query from the ASX. The company clarified that it is not aware of any undisclosed information that could explain the trading activity. However, it acknowledged the public release of an ‘untitled letter’ from the FDA regarding promotional claims for its product NEXTSTELLIS®, which may have led to market speculation. Mayne Pharma is preparing a response to the FDA and plans to address market concerns through a further announcement.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited addressed a compliance issue regarding the late lodgement of an Appendix 3Y for a change in a director’s interest, attributing the delay to an administrative oversight. The company is reviewing its internal processes to prevent future occurrences and has reinforced its commitment to timely disclosure by reminding directors of their obligations under Listing Rule 3.19A. This incident highlights the importance of robust compliance mechanisms for maintaining transparency and trust with stakeholders.
Mayne Pharma Group Limited announced the cessation of 17,656 performance rights due to unmet conditions, effective May 5, 2025. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting on the company’s operational adjustments and strategic focus.
Mayne Pharma Group Limited has announced that a key condition under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition by Cosette Pharmaceuticals has been satisfied. The scheme of arrangement, which involves Cosette acquiring all shares in Mayne Pharma, still requires approval from the Foreign Investment Review Board, Mayne Pharma shareholders, and final court approval, with the timeline remaining as previously indicated.
UBS Group AG and its related bodies corporate have increased their voting power in Mayne Pharma Group Limited from 7.40% to 8.79% as of April 24, 2025. This change in substantial holding reflects UBS’s strategic interest in Mayne Pharma, potentially impacting the company’s market influence and shareholder dynamics.
Mayne Pharma Group Limited has reported a 5% increase in unaudited group revenues to approximately $300 million for the first nine months of the 2025 financial year, driven by significant growth in Women’s Health. However, the company faced challenges in the Dermatology segment due to market declines and competition. The company has entered a new licensing agreement with Sol-Gel Technologies to acquire US rights to TWYNEO® and EPSOLAY®, enhancing its dermatology portfolio. This strategic move is expected to drive growth and align with Mayne Pharma’s strategy to improve market access for innovative products. The company anticipates a strong financial performance in FY25, with expected underlying EBITDA growth of 105-123% over FY24, and plans to focus on sales execution and marketing efforts across its segments.
UBS Group AG and its related entities have increased their voting power in Mayne Pharma Group Limited from 6.38% to 7.40%, as of April 14, 2025. This change in substantial holding indicates a growing interest and investment in the company, potentially impacting its market positioning and signaling confidence in its future prospects.
Mayne Pharma Group Limited is involved in a legal proceeding initiated by TherapeuticsMD, Inc. in the United States, alleging various breaches related to a Transaction Agreement from December 2022. Mayne Pharma plans to defend the claims vigorously and has counterclaims against TherapeuticsMD, asserting damages exceeding those claimed by the plaintiff. The company denies any wrongdoing and maintains that the proceeding will not affect existing agreements or rights concerning licensed products.
State Street Corporation and its subsidiaries have ceased to be substantial holders in Mayne Pharma Group as of April 7, 2025. This change in substantial holding could impact the company’s shareholder dynamics and influence its market positioning, as State Street’s involvement in the company has altered.
State Street Corporation, through its subsidiaries such as State Street Global Advisors and State Street Bank and Trust Company, has become a substantial holder in Mayne Pharma Group Limited. This development indicates a significant investment and interest in Mayne Pharma, potentially impacting the company’s market position and signaling confidence in its future prospects.
UBS Group AG and its related bodies corporate have reduced their voting power in Mayne Pharma Group Limited from 9.02% to 7.47% as of March 10, 2025. This change in substantial holding may impact the company’s shareholder dynamics and influence its future strategic decisions, potentially affecting stakeholders’ interests.
UBS Group AG and its related bodies corporate have increased their voting power in Mayne Pharma Group Limited from 6.32% to 9.02%, as of March 7, 2025. This change in substantial holding could potentially impact the company’s strategic decisions and influence its market positioning, reflecting UBS’s growing interest and investment in the pharmaceutical sector.
Insignia Financial Ltd has announced that it has ceased to be a substantial holder in Mayne Pharma Group Limited as of March 4, 2025. The notice details various transactions involving the purchase and sale of shares by Insignia Financial Ltd and its subsidiaries, indicating a significant reduction in their holdings in Mayne Pharma. This change in substantial holding may impact Mayne Pharma’s shareholder structure and could influence its market perception and stock performance.